Why should frailty be considered a dynamic factor in MM and when should it be assessed?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Hira Mian, McMaster University, Hamilton, CA. We asked, Why should frailty be considered a dynamic factor in multiple myeloma (MM) and when should it be assessed?

In this interview, Mian looks at frailty as a predictor of outcomes, such as overall survival and toxicity rates, in patients with MM. Mian outlines how in current practice frailty is often only assessed at diagnosis and therefore there is a gap in understanding how frailty changes, as well as the changing need for therapy escalation or de-escalation. Mian goes on to outline their research study entitled “Need for dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study”, and concludes with the results and implications of this study, including the dynamic nature of frailty and the optimum time to reassess frailty post-diagnosis, which ultimately can help tailor treatment.